The abstract is read at the publisher; the summary is JClub's.
In a single-centre UK cohort of 2,054 palliative-intent ICI patients, mRNA COVID-19 vaccination showed a significant OS association only in the extended window (HR 0.59; 95% CI 0.46–0.76; p<0.001).
- Why it matters: Timing of COVID-19 vaccination relative to immune checkpoint inhibitor therapy may change any survival relationship, but prior evidence has not clarified how exposure windows affect results.
- What they did: Using multivariable Cox models with baseline hazard stratified by tumour group, the study compared OS across two vaccination exposure definitions: ±100 days around the first ICI cycle versus ±100 days around the first through final ICI cycle.
- The result: The initial fixed-window analysis was non-significant for mRNA (HR 0.80; 95% CI 0.60–1.06; p=0.123), and calendar-restricted and supportive time-varying analyses attenuated the extended-window mRNA association (HR 0.82; 95% CI 0.66–1.04; p=0.099).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.